source
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
- Star raises $200 million after successful spinouts of Electra and Vega TherapeuticsStar, a biopharma company, announced it has secured $200 million in new funding. The capital follows the recent exits of its subsidiaries Electra Therapeutics and Vega Therapeutics, which were spu…